Denali Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $23.73
- Today's High:
- $24.305
- Open Price:
- $23.88
- 52W Low:
- $20.76
- 52W High:
- $39.43
- Prev. Close:
- $23.93
- Volume:
- 411932
Company Statistics
- Market Cap.:
- $4.17 billion
- Book Value:
- 7.07
- Revenue TTM:
- $101.46 million
- Operating Margin TTM:
- -389.36%
- Gross Profit TTM:
- $-250269000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -18.09%
- Return on Equity TTM:
- -39.32%
Company Profile
Denali Therapeutics Inc had its IPO on 2017-12-08 under the ticker symbol DNLI.
The company operates in the Healthcare sector and Biotechnology industry. Denali Therapeutics Inc has a staff strength of 430 employees.
Stock update
Shares of Denali Therapeutics Inc opened at $23.88 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $23.73 - $24.31, and closed at $24.13.
This is a +0.84% increase from the previous day's closing price.
A total volume of 411,932 shares were traded at the close of the day’s session.
In the last one week, shares of Denali Therapeutics Inc have increased by +3.52%.
Denali Therapeutics Inc's Key Ratios
Denali Therapeutics Inc has a market cap of $4.17 billion, indicating a price to book ratio of 4.7475 and a price to sales ratio of 35.6178.
In the last 12-months Denali Therapeutics Inc’s revenue was $101.46 million with a gross profit of $-250269000 and an EBITDA of $-376710016. The EBITDA ratio measures Denali Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Denali Therapeutics Inc’s operating margin was -389.36% while its return on assets stood at -18.09% with a return of equity of -39.32%.
In Q1, Denali Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 16.6%.
Denali Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Denali Therapeutics Inc’s profitability.
Denali Therapeutics Inc stock is trading at a EV to sales ratio of 25.3642 and a EV to EBITDA ratio of -9.2316. Its price to sales ratio in the trailing 12-months stood at 35.6178.
Denali Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.41 billion
- Total Liabilities
- $391.08 million
- Operating Cash Flow
- $-92715000.00
- Capital Expenditure
- $2.79 million
- Dividend Payout Ratio
- 0%
Denali Therapeutics Inc ended 2024 with $1.41 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.41 billion while shareholder equity stood at $966.71 million.
Denali Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $391.08 million in other current liabilities, 1694000.00 in common stock, $-1080768000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $68.13 million and cash and short-term investments were $1.29 billion. The company’s total short-term debt was $6,539,000 while long-term debt stood at $0.
Denali Therapeutics Inc’s total current assets stands at $1.33 billion while long-term investments were $0 and short-term investments were $1.22 billion. Its net receivables were $0 compared to accounts payable of $2.22 million and inventory worth $0.
In 2024, Denali Therapeutics Inc's operating cash flow was $-92715000.00 while its capital expenditure stood at $2.79 million.
Comparatively, Denali Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $24.13
- 52-Week High
- $39.43
- 52-Week Low
- $20.76
- Analyst Target Price
- $58.71
Denali Therapeutics Inc stock is currently trading at $24.13 per share. It touched a 52-week high of $39.43 and a 52-week low of $39.43. Analysts tracking the stock have a 12-month average target price of $58.71.
Its 50-day moving average was $26.17 and 200-day moving average was $27.61 The short ratio stood at 12.15 indicating a short percent outstanding of 0%.
Around 1458.9% of the company’s stock are held by insiders while 7922.2% are held by institutions.
Frequently Asked Questions About Denali Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson’s disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer’s disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer’s disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.